- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Kardigan, Inc. Common Stock(KARD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for KARD
11/13/2026: KARD (1-star) is currently NOT-A-BUY. Pass it for now.
Kardigan is a clinical-stage biopharmaceutical company focused on developing precision therapeutics for cardiovascular diseases. The company's primary strengths lie in its specialized pipeline—including drug candidates like Danicamtiv and Ataciguat—and its AI-driven cardiac intelligence platform. Its core investment opportunity centers on advancing these targeted treatments through mid-stage trials to address high-unmet-need conditions. However, investors face notable risks typical of pre-commercial biotech firms, including clinical trial uncertainty, high cash burn, and intense industry competition. The stock suits growth-oriented investors with high risk tolerance who are willing to monitor upcoming clinical data catalysts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Kardigan offers high-growth exposure to clinical-stage cardiovascular precision therapeutics and AI-driven drug discovery. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience sharp price movements around clinical trial readouts and regulatory catalysts. |
| Value investor | Weak fit | As a pre-profitability clinical-stage biotech firm, it lacks traditional value metrics like positive earnings or price-to-earnings ratios. |
| Dividend investor | Weak fit | The company does not pay dividends, retaining all capital for research and clinical trial execution. |
| Low-risk investor | Weak fit | High clinical development risks and share price volatility make it unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks frequently experience significant price swings based on clinical trial updates and market sentiment. |
| Valuation risk | High | Valuations are heavily dependent on future pipeline success rather than current earnings or revenue. |
| Competition risk (cardiovascular drug development) | Medium / high | Large pharmaceutical competitors possess vastly superior financial and commercial resources. |
| Business quality | Medium | The company features a specialized scientific platform but lacks an established commercial product portfolio. |
| Dividend income | Low / none | No dividend distributions are paid to shareholders. |
| Execution risk | High | Success relies entirely on successful clinical trial readouts, regulatory approvals, and eventual commercial execution. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.29B USD | Price to earnings Ratio - | 1Y Target Price 41 |
Price to earnings Ratio - | 1Y Target Price 41 | ||
Volume (30-day avg) 566.7K shares | Beta - | 52 Weeks Range 12.23 - 27.00 | Updated Date 11/15/2026 |
52 Weeks Range 12.23 - 27.00 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.65 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Insufficient Data
The stock demonstrates a Insufficient Data price path pattern.

Insufficient Data
The stock price exhibits a Insufficient Data stability pattern.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Therapeutic Pipeline Development | Future commercialization rights and potential milestone or licensing agreements derived from drug candidates like Danicamtiv and Ataciguat. | The company currently generates zero commercial revenue and operates at a loss while funding clinical trials. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 710.20M | Price to Sales(TTM) - |
Enterprise Value 710.20M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 93.60M | Shares Floating 51.85M |
Shares Outstanding 93.60M | Shares Floating 51.85M | ||
Percent Insiders 16.36 | Percent Institutions 84.23 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

